SynthesisPloS one2012
Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Synthesis in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Environmental exposures in autoimmune inflammatory rheumatic diseases: a priority-based evidence map, immune-mechanism integration audit and research agenda.Frontiers in immunology · 2026Pooled it
- Occupational and environmental scleroderma. Systematic review and meta-analysis.Clinical rheumatology · 2017Pooled it
- How do autoimmune diseases cluster in families? A systematic review and meta-analysis.BMC medicine · 2013Pooled it
- Quality Evaluation Considerations for Stem Cell-Derived Extracellular Vesicles-Based Therapeutic Products in China.Journal of extracellular vesicles · 2026Review
- Environmental and occupational contributors to autoimmune, inflammatory, and musculoskeletal rheumatic disease: a review of emerging evidence and clinical implications.Current opinion in rheumatology · 2026Review
- Towards primary prevention of multiple sclerosis.Nature reviews. Neurology · 2026Review
- Chromosomal Instability and Telomere Attrition in Systemic Sclerosis: A Historical Perspective.Genes · 2025Review
- Occupational dust and chemical exposures and the development of autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2025Review
- Occupational history questionnaire for job coding and exposure assessment in systemic autoimmune rheumatic diseases.Rheumatology advances in practice · 2025Article
- Pulmonary vascular disease, environmental pollution, and climate change.Pulmonary circulation · 2024Review
- No causal association between pneumoconiosis and three inflammatory immune diseases: a Mendelian randomization study.Frontiers in public health · 2024Article
- Solvent-Induced Raynaud's Phenomenon.Cureus · 2023Article
- Gene-environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures.Journal of neurology, neurosurgery, and psychiatry · 2023Article
- Parental occupational exposure to solvents and autism spectrum disorder: An exploratory look at gene-environment interactions.Environmental research · 2023Article
- Association between exposure to combustion-related air pollution and multiple sclerosis risk.International journal of epidemiology · 2023Article
- Toxic Occupational Exposures and Membranous Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2022Observational
- Cognitive Impairment and Neurodegenerative Diseases Development Associated with Organophosphate Pesticides Exposure: a Review Study.Neurotoxicity research · 2022Review
- Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- The Relationship between 9/11 Exposure, Systemic Autoimmune Disease, and Post-Traumatic Stress Disorder: A Mediational Analysis.International journal of environmental research and public health · 2022Article
- Volatile organic compounds: A proinflammatory activator in autoimmune diseases.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenetic and epigenetic factors interacting with the environment over time are the main causes of complex diseases such as autoimmune diseases (ADs). Among the environmental factors are organic solvents (OSs), which are chemical compounds used routinely in commercial industries. Since controversy exists over whether ADs are caused by OSs, a systematic review and meta-analysis were performed to assess the association between OSs and ADs. METHODS AND
findingsThe systematic search was done in the PubMed, SCOPUS, SciELO and LILACS databases up to February 2012. Any type of study that used accepted classification criteria for ADs and had information about exposure to OSs was selected. Out of a total of 103 articles retrieved, 33 were finally included in the meta-analysis. The final odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by the random effect model. A sensitivity analysis confirmed results were not sensitive to restrictions on the data included. Publication bias was trivial. Exposure to OSs was associated to systemic sclerosis, primary systemic vasculitis and multiple sclerosis individually and also to all the ADs evaluated and taken together as a single trait (OR: 1.54; 95% CI: 1.25-1.92; p-value<0.001).
conclusionExposure to OSs is a risk factor for developing ADs. As a corollary, individuals with non-modifiable risk factors (i.e., familial autoimmunity or carrying genetic factors) should avoid any exposure to OSs in order to avoid increasing their risk of ADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.